Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma

M. Gobbi, M. Cavo, P. L. Tazzari, A. Dinota, C. Tassi, A. Bontadin i, L. Albertazzi, C. Miggiano, S. Rizzi, G. Rosti, A. Bolognesi, F. Stirpe, S. Tura

Research output: Contribution to journalArticlepeer-review


A system to purge the bone marrow of myeloma cells has been developed in our laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody - that recognizes plasma cells and B-cell precursors - and the ribosome-inactivating protein momordin. 8 patients have so far been treated. 4 are surviving from 4 to 18 months after ABMT, whereas 4 died after 1 to 6 months, 2 from infections, 1 from relapsing disease and 1 from veno-occlusive disease. A marked tumour reduction was observed in all evaluable patients; however, none has achieved complete disappearance of the disease. The haemopoietic reconstitution was significantly delayed in 3 patients. These preliminary results show the feasibility of this approach in advanced MM patients with heavily infiltrated marrow. The place of ABMT in the treatment of MM remains to be determined; the selection of patients with still responding and less advanced disease would probably produce better results.

Original languageEnglish
Pages (from-to)176-181
Number of pages6
JournalEuropean Journal of Haematology, Supplement
Issue number51
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma'. Together they form a unique fingerprint.

Cite this